Highlights of John Castellani’s CNBC Squawk Box Appearance

04.11.11 By Grady Forrer

Day Two
[10:05 a.m.]

Two Women Scientists Honored with PhRMA’s 2011 Discoverers Award

New Survey Emphasizes Value of Biopharmaceutical Company Engagement With Healthcare Providers

Washington, D.C. (March 29, 2011) — Nearly eight out of 10 physicians view pharmaceutical research companies and their sales representatives as useful sources of information on prescription medicines, according to a survey released today by KRC Research.

PhRMA Statement on AARP Report

Washington, D.C. (March 28, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President Karl Uhlendorf issued the following statement:

“AARP again is ignoring the key facts about the marketplace for prescription medicines.

“Growth in spending for prescription medicines has slowed to historic lows. According to IMS Health, prescription drug spending will grow between three percent and five percent this year, and at 3.5 percent annually through 2013.

PhRMA Statement on the Earthquake in Japan

Washington, D.C. (March 16, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani today released the following statement:

PhRMA Statement on President’s Budget Proposal

Washington, D.C. (February 14, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani today released the following statement on the White House's fiscal year 2012 budget:

"PhRMA is disappointed that the President’s budget proposal would diminish crucial incentives for future U.S. medical innovations.

PhRMA Statement on Creation of U.S. Canada Regulatory Cooperation Council

Washington, D.C. (Feb. 8, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today upon the creation of the U.S. Canada Regulatory Cooperation Council (RCC):

“PhRMA is pleased that the both the U.S. and Canadian governments realize that greater regulatory harmonization and transparency will promote job growth, innovation and better health and welfare for the citizens of our countries.

PhRMA Statement on Medical Innovation

Washington, D.C. (November 4, 2010) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Wes Metheny issued the following statement today regarding the Cleveland Clinic’s Top 10 Medical Innovations for 2011:

“The Cleveland Clinic’s list of the top medical innovations presents an important reminder that despite recent economic challenges, the commitment to development of groundbreaking new therapies remains strong.

PhRMA Statement on Patent Settlements

Washington, D.C. (June 28, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding patent settlement language in the House war supplemental bill:

“Patent settlements are a vital aspect of the ability to protect intellectual property. PhRMA believes including the provision on restricting patent settlements can discourage pro-consumer settlements that often bring generics to market years before patent expiration.

‘Sharing Miracles’ Television Program to Feature Major League Baseball Hall of Famer Don Sutton

Washington, D.C. (June 9, 2010) – Legendary pitcher Don Sutton will appear on June’s episode of Sharing Miracles – a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs on more than 300 television stations nationwide.

Sutton retired from the majors in 1988 after a remarkable 22-year career in which he won more than 300 games and struck out more than 3,000 batters – one of only 10 pitchers in Major League Baseball history to do so.

PhRMA Statement on House Patent Bill

Washington, D.C. (May 17, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson today issued the following statement regarding a proposal to allow the Patent and Trademark Office to collect fees on patent applications:

“Rep. Conyers’s proposal to grant the Patent and Trademark Office the authority to set fees on patent applications, while well-intentioned, would act as an additional tax on businesses as well as on the innovation that patents are intended to protect.

Pages

Subscribe to RSS - Opinion